Publications by authors named "Andrew Chilelli"

Claim this Profile
C
Cost-effectiveness of enzalutamide with androgen-deprivation therapy (ADT) versus ADT alone for the treatment of high-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer in Canada.
Armen Aprikian, Fred Saad, Ewa Wywial, Thomas McLean, Karissa Johnston, Andrew Chilelli

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Observational Health Data Analysis of the Cardiovascular Adverse Events of Systemic Treatment in Patients with Metastatic Hormone-sensitive Prostate Cancer: Big Data Analytics Using the PIONEER Platform.
Pawel Rajwa, Angelika Borkowetz, Thomas Abbott, Andrea Alberti, Katharina Beyer, Andrew Chilelli

Eur Urol Focus· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methodological approach to optimize a step-by-step deterministic linkage of SNDS data with a clinical database (FREGAT) of gastric/gastroesophageal junction adenocarcinoma in France: Pitfalls and learnings.
Magali Laborey, Audrey Lajoinie, Jonatan Freilich, Emmanuelle Samalin, Olivier Bouché, Andrew Chilelli

PLoS One· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar's Letter to the Editor re: Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9.
Amit Bahl, Andrew Chilelli, Rita Faria, Nigel Rozario, Robert Snijder

World J Urol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing the safety and efficacy of systemic therapies for high-risk biochemically recurrent hormone-sensitive prostate cancer: a network meta-analysis.
Armen Aprikian, Andrew Chilelli, Thomas McLean, Anchen Nasr, Arijit Ganguli

Front Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study.
Amit Bahl, Andrew Chilelli, Rita Faria, Nigel Rozario, Robert Snijder

World J Urol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study.
Axel S Merseburger, Eugen Dornstauder, Carsten-Henning Ohlmann, Armen Aprikian, Sophia Junker, Andrew Chilelli

Adv Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment intensification in metastatic castration-sensitive prostate cancer: a real-world study in Alberta, Canada.
Steven M Yip, Winson Y Cheung, Armen Aprikian, Matthias Stoelzel, Kelvin Wong, Andrew Chilelli

Future Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attributes and Health Care Resource Utilization of Patients on Enzalutamide or Abiraterone for Metastatic Castration-Resistant Cancer in England.
Amit Bahl, Rita Faria, Axel S Merseburger, Gert Attard, Robert Snijder, Andrew Chilelli

JCO Oncol Pract· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings.
Armen Aprikian, Amit Bahl, Aurelius Omlin, Giulia Baciarello, Abhiroop Chakravarty, Andrew Chilelli

Front Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide versus abiraterone acetate in the development of new-onset or worsening type 2 diabetes mellitus in patients with metastatic castration-resistant prostate cancer: EVADE study.
Amit Bahl, Hanna Sodatonou, Robert Snjider, Andrew Chilelli, Alessandra Pranzo

World J Urol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Research Protocol for an Observational Health Data Analysis on the Adverse Events of Systemic Treatment in Patients with Metastatic Hormone-sensitive Prostate Cancer: Big Data Analytics Using the PIONEER Platform.
Pawel Rajwa, Angelika Borkowetz, Thomas Abbott, Andrea Alberti, Anders Bjartell, Andrew Chilelli

Eur Urol Open Sci· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada.
Fred Saad, Andrew Chilelli, Benny Hui, Sergey Muratov, Arijit Ganguli

J Med Econ· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating Metrics Applied to the Medical Science Liaison (MSL) Role: A Survey-Based Study of Canadian MSL Leaders.
Munaza Saleem, Lisa Cesario, Lisa Wilcox, Marsha Haynes, Simon Collin, Andrew Chilelli

Ther Innov Regul Sci· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis